Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Daiichi Sankyo Buys Shanghai Xinshengyuan Pharma

publication date: Apr 20, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Daiichi Sankyo's China subsidiary has gained control of Shanghai Xinshengyuan Pharmaceutical Group Medicine & Chemical Reagents Sales Co., a company that imports Ranbaxy's generic drug portfolio into China. Daiichi and Ranbaxy are already partners. In 2008, Daiichi Sankyo paid $4.6 billion for a controlling interest in Ranbaxy, adding generic drugs to Daiichi Sankyo's portfolio of innovative drugs. By buying Xinshengyuan, Daiichi gains control of its partner's products in China. More details....

Stock Symbols: (TO: 4658) (BSE: 500359)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners